Host-directed and immune-based therapies for human immunodeficiency virus infection

Annals of Internal Medicine

Volumn 122, Issue 3, 1995, Pages 218-222

  Lederman, Michael M ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; CD4 ANTIGEN; GLUTATHIONE; PENTOXIFYLLINE; [7 CHLORO 5 (1H PYRROL 2 YL) 3H BENZO[E][1,4]DIAZEPIN 2 YL]METHYLAMINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; VIRUS CELL INTERACTION;

EID: 0028868139     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-122-3-199502010-00010     Document Type: Review

References (74)

1. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1987;317:185-91.
2. de Wolf F, Lange JM, Goudsmit J, Cload P, de Gans J, Schellekens PT, et al. Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects. Lancet. 1988;1:373-6.
3. Yarchoan R, Klecker RW, Weinhold KJ, Markham PD, Lyerly HK, Durack DT, et al. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986;1:575-80.
4. Clerici M, Landay AL, Kessler HA, Phair JP, Venzon DJ, Hendrix CW, et al. Reconstitution of long-term T helper cell function after zidovudine therapy in human immunodeficiency virus-infected patients. J Infect Dis. 1992;166:723-30.
5. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989;246:1155-8.
6. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989; 243:1731-4.
7. Saag MS, Emini EA, Laskin OL, Douglas J, Lapidus WI, Schleif WA, et al. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N Engl J Med. 1993;329:1065-72.
8. Wilde MI, Langtry HD. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1993;46:515-78.
9. Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science. 1988;242:1171-3.
10. Saag MS, Hahn BH, Gibbons J, Li Y, Parks ES, Parks WP, et al. Extensive variation of human immunodeficiency virus type-1 in vivo. Nature. 1988;334:440-4.
11. Lancy ED, Lifsics MR, Kehres DG, Maurer R. Isolation and characterization of mutants with deletions in dnaQ, the gene for the editing suhunit of DNA polymerase III in Salmonella typhimurium. J Bacteriol. 1989;171:5572-80.
12. Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC, et al. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature. 1993;361:650-4.
13. Piatak M Jr, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 1993;259:1749-54.
14. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992;326:1514-21.
15. Iseman, MD, Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993;329:784-91.
16. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984;312:763-7.
17. Hildreth JE, Orentas RJ. Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation. Science. 1989;244: 1075-8.
18. lys. Eur J Biochem. 1989;184:367-74.
19. Gulizia J, Dempsey MP, Sharova N, Bukrinsky MI, Spitz L, Goldfarb D, et al. Reduced nuclear import of human immunodeficiency virus type 1 preintegration complexes in the presence of a prototypic targeting signal. J Virol. 1994;68:2021-5.
20. Reddy EP, Dasgupta P. Regulation of HIV-1 gene expression by cellular transcription factors. Pathobiology. 1992;60:219-24.
21. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature. 1987; 326:711-3.
22. Cullen BR. Does HlV-1 Tat induce a change in viral initiation rights? Cell. 1993;73:417-20.
23. Malim MH, Cullen BR. Rev and the fate of pre-mRNA in the nucleus: implications for the regulation of RNA processing in eukaryotes. Mol Cell Biol. 1993;13:6180-9.
24. Luo Y, Yu H, Peterlin BH. Cellular protein modulates effects of human immunodeficiency virus type 1 Rev. J Virol. 1994;68:3850-6.
25. McCune JM, Rabin LB, Feinberg MB, Lieberman M, Kosek JC, Reyes GR, et al. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell. 1988;53:55-67.
26. Guy B, Kieny MP, Riviere Y, Le Peuch C, Dott K, Girard M, et al. HIV F/3′ orf encodes a phosphorylated GTP-binding protein resembling an oncogene product. Nature. 1987;330:266-9.
27. Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell. 1993;73:1067-78.
28. Kundig TM, Schorle H, Bachmann MF, Hengartner H, Zinkernagel RM, Horak I. Immune responses in interleukin-2-deficient mice. Science. 1993;262:1059-61.
29. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science. 1993;262:1011-8.
30. Paietta E, Saltzman B, Klein RS, Friedland GH, Wiernik PH, Stein H. Expression of activation antigen on lymphocytes in the acquired immunodeficiency syndrome [Letter]. Ann Intern Med. 1986;104:890-1.
31. Lederman MM, Carey JT, Schacter B, Aucott J, Ellner JJ. Lymphocytes of persons with the acquired immunodeficiency syndrome and related conditions express reactivity with the monoclonal antibody 4D12 reflective of in vivo lymphocyte activation. Hum Immunol. 1987; 20:279-91.
32. Vanham G, Kostens L, Gigase P, Colebunders R, Vandebruaene M, Brijs L, et al. Evidence for circulating activated cytotoxic T cells in HIV-infected subjects before the onset of opportunistic infections. Clin Exp Immunol. 1990;82:3-9.
33. Lederman MM, Carey JT, Purvis S. Autologous killing by lymphocytes of persons infected by the human immunodeficiency virus. In: Andrieu JM, Bach JF, Even P, eds. Autoimmune Aspects of HIV Infection. New York: Royal Society of Medicine Services;1988:165-74.
34. Tyler DS, Nastala CL, Stanley SD, Matthews TJ, Lyerly HK, Bolognesi DP, et al. GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody. J Immunol. 1989;142:1177-82.
35. Israel-Biet D, Venet A, Beldjord K, Andrieu JM, Even P. Autoreactive cytotoxicity in HIV-infected individuals. Clin Exp Immunol. 1990;81: 18-24.
36. Siliciano RF, Lawton T, Knall C, Karr RW, Berman P, Gregory T, et al. Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ cell depletion. Cell. 1988;54:561-75.
37. Lederman MM, Purvis SF, Walter EI, Carey JT, Medof ME. Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor. Proc Natl Acad Sci U S A. 1989;86:4205-9.
38. Dorsett BH, Cronin W, Ioachim HL. Presence and prognostic significance of antilymphocyte antibodies in symptomatic and asymptomatic human immunodeficiency virus infection. Arch Intern Med. 1990;150: 1025-8.
39. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science. 1987;238:800-2.
40. Poli G, Fauci AS. The effect of cytokines and pharmacologic agents on chronic HIV infection. AIDS Res Hum Retroviruses. 1992;8:191-7.
41. Lahdevirta J, Maury CP, Teppo AM, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med. 1988;85:289-91.
42. Nair BC, DeVico AL, Nakamura S, Copeland TD, Chen Y, Patel A, et al. Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin M. Science. 1992;255:1430-2.
43. Miles SA, Martinez-Maza O, Rezai A, Magpantay L, Kishimoto T, Nakamura S, et al. Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science. 1992;255:1432-4.
44. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC, et al. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med. 1992;175:331-40.
45. Banda NK, Bernier J, Kurahara DK, Kurrle R, Haigwood N, Sekaly RP, et al. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med. 1992;176: 1099-106.
46. Smith DH, Byrn RA, Marsters SA, Gregory T, Groopman JE, Capon DJ, et al. Blocking of HIV-1 infectivity by a soluble, secreted from of the CD4 antigen. Science. 1987;238:1704-7.
47. Moore JP, McKeating JA, Weiss RA, Sattentau QJ. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science. 1990;250: 1139-42.
48. Schacker T, Coombs RW, Collier AC, Zeh JE, Fox I, Alam J, et al. The effects of high-dose recombinant soluble CD4 on human immunodeficiency virus type 1 viremia. J Infect Dis. 1994;169:37-40.
49. Daar ES, Li XL, Moudgil T, Ho DD. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A. 1990; 87:6574-8.
50. Haubrich RH. A randomized study of safety, tolerance, pharmacokinetics and activity of oral Ro-24-7429 (Tat antagonist) in patients with HIV infection [Abstract]. In: IXth International Conference on AIDS. Berlin: Institute for Clinical and Experimental Virology of the Free University of Berlin; 1993.
51. Eck HP, Gmunder H, Hartmann M, Petzoldt D, Daniel V, Droge W, et al. Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1-infected patients. Biol Chem Hoppe Seyler. 1989; 370:101-8.
52. Buhl R, Jaffe HA, Holroyd KJ, Wells FB, Mastrangeli A, Saltini C, et al. Systematic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet. 1989;1294-8.
53. Roederer M, Staal FJ, Raju PA, Ela SW, Herzenberg LA, Herzenberg LA. Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proc Natl Acad Sci U S A. 1990;87: 4884-8.
54. Kalebic T, Kinter A, Poli G, Anderson ME, Meister A, Fauci AS. Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine. Proc Natl Acad Sci U S A. 1991;88:986-90.
55. Lederman MM, Georges D, Borum P, Goldberg D. L-2 Oxothiazolidine-4-carboxylate (Procysteine) inhibits HIV-1 expression but not interleukin-2 secretion. IXth International Conference on AIDS, PO A29-0681, Berlin, June, 1993.
56. R L-2 oxothiazolidine-4-carboxylic acid. IXth International Conference on AIDS, PO B29-2181, Berlin, June, 1993.
57. Dezube BJ, Pardee AB, Chapman B, Beckett LA, Korvick JA, Novick WJ, et al. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group. J Acquir Immune Defic Syndr. 1993;6:787-94.
58. Mole L, Margolis D, Ghotbi L, Holodniy M. The use of pentoxifylline alone in HIV-infected patients [Letter]. J Acquir Immune Defic Syndr. 1994;7:519-21.
59. Luke DR, McCreedy BJ, Sarnoski TP, Bookout JB, Johnston AM, Lell JE. Phase I/II study of pentoxifylline with zidovudine on HIV-1 growth in AIDS patients. Int J Clin Pharmacol Ther Toxicol. 1993;31:343-50.
60. Takashima T, Ueta C, Tsuyuguchi I, Kishimoto S. Production of tumor necrosis factor alpha by monocytes from patients with pulmonary tuberculosis. Infect Immun. 1990;58:3286-92.
61. Biswas DK, Ahlers CM, Dezube BJ, Pardee AB. Cooperative inhibition of NF-kappa B and Tat-induced superactivation of human immunodeficiency virus type 1 long terminal repeat. Proc Natl Acad Sci U S A. 1993;90:11044-8.
62. Schmidt A, Hennighausen L, Siebenlist U. Inducible nuclear factor binding to the kappa B elements of the human immunodeficiency virus enhancer in T cells can be blocked by cyclosporin A in a signal-dependent manner. J Virol. 1990;64:4037-41.
63. Phillips A, Wainberg MA, Coates R, Klein M, Rachlis A, Read S, et al. Cyclosporine-induced deterioration in patients with AIDS. Can Med Assoc J. 1989;140:1456-60.
64. Fliri H, Baumann G, Enz A, Kallen J, Luyten M, Mikol V, et al. Cyclosporins. Structure-activity relationships. Ann N Y Acad Sci. 1993; 696:47-53.
65. Lane HC, Davey V, Kovacs JA, Feinberg J, Metcalf JA, Herpin B, et al. Interferon-α in patients with asymptomatic human immunodeficiency virus (HIV) infection. Ann Intern Med. 1990;112:805-11.
66. Miles SA, Wang H, Cortes E, Carden J, Marcus S, Mitsuyasu RT. Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections. Ann Intern Med. 1990;112:582-9.
67. Teppler H, Kaplan G, Smith KA, Montana AL, Meyn P, Cohn ZA. Prolonged immunostimulatory effects of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection. J Exp Med. 1993;177:483-92.
68. Kovacs JA, Vogel S, Falloon J, Polis MA, Walker RE, Lane HC, et al. Intermittent interleukin-2 therapy leads to sustained increases in CD4 counts in some HIV-infected patients. 1993; IX Int Conf on AIDS. Abstract B-28-2156. Berlin, June 6-11.
69. Clerici M, Lucey DR, Berzofsky JA, Pinto LA, Wynn TA, Blatt SP, et al. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science. 1993;262:1721-4.
70. Ojwang JO, Hampel A, Looney DJ, Wong-Staal F, Rappaport J. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc Natl Acad Sci U S A. 1992;89:10802-6.
71. Pearson L, Garcia J, Wu F, Modesti N, Nelson J, Gaynor R. A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci U S A. 1990;87:5079-83.
72. Malim MH, Freimuth WW, Liu J, Boyle TJ, Lyerly HK, Cullen BR, et al. Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J Exp Med. 1992; 176:1197-201.
73. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell. 1990;63:601-8.
74. Lee TC, Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. New Biol. 1992;4:66-74.